Reductions in liver enzymes are associated with anti‐hyperglycaemic and anti‐obesity effects of tofogliflozin in people with type 2 diabetes: Post‐hoc analyses
Endocrinology, Diabetes & Metabolism · 2024
DOI: 10.1002/edm2.461 ↗At a glance
Journal article in Endocrinology, Diabetes & Metabolism, 2024. Written by Toshinari Takamura and 5 co-authors. Institution: Department of Endocrinology and Metabolism, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan. Major MEDLINE topics: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Hyperglycemia, Benzhydryl Compounds. Cited 1 times so far (Crossref); 30 references. The full text is freely available (open access, CC BY 4.0).
Topics: Diabetes mellitus
Abstract (original language)
Aims
How the pathology of type 2 diabetes (T2D), including hyperglycaemia and obesity, affects liver enzymes has not been clinically demonstrated. Thus, we compared time courses of gamma‐glutamyltransferase (GGT) and alanine aminotransferase (ALT) with those of fasting plasma glucose (FPG) and body weight (BW) during treatment with the SGLT2 inhibitor tofogliflozin for T2D. Materials and Methods We post‐hoc analysed preexisting data on 1046 people with T2D administered tofogliflozin or placebo for 24 weeks in four tofogliflozin studies. First, time courses of percent changes in variables during the intervention were analysed using a mixed effect model to explore the similarity of the time courses and to evaluate time‐treatment interactions. Second, clinical factors related to the percent changes in GGT and ALT were clarified using multivariate analyses.
Results
GGT levels and FPG values rapidly and significantly decreased via tofogliflozin as early as week 4, with decreases maintained until week 24. Conversely, BW and ALT decreased progressively until week 24. Time courses of FPG ( p = .365, time‐treatment interaction) and GGT ( p = .510) reductions were parallel between tofogliflozin and placebo from weeks 4 to 24, while BW and ALT reductions ( p < .001, respectively) were not. Reductions in GGT at week 24 were associated with reductions in FPG and BW at week 24, whereas ALT reductions were only associated with reductions in BW.
Conclusions
Reductions in GGT and ALT were associated with the anti‐hyperglycaemic and anti‐obesity effects of tofogliflozin, respectively, in people with T2D. Therefore, GGT and ALT may be surrogate markers for hyperglycaemia and obesity in T2D.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Endocrinology and Metabolism, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan.
- Department of Internal Medicine, Kawasaki Medical School, Kurashiki, Japan.
- Kowa Co., Ltd., Tokyo, Japan.
- Department of Hygiene and Public Health, , Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan.
- Clinical Data Science Department, Kowa Co., Ltd., Tokyo, Japan.
ORCID profiles: Toshinari Takamura, Kohei Kaku, Hideki Suganami
Cite
APA
Takamura, T., Kaku, K., Yoshida, A., Kusakabe, H., Nakamura, H., & Suganami, H. (2024). Reductions in liver enzymes are associated with anti‐hyperglycaemic and anti‐obesity effects of tofogliflozin in people with type 2 diabetes: Post‐hoc analyses. Endocrinology, Diabetes & Metabolism. https://doi.org/10.1002/edm2.461
Vancouver
Takamura T, Kaku K, Yoshida A, Kusakabe H, Nakamura H, Suganami H. Reductions in liver enzymes are associated with anti‐hyperglycaemic and anti‐obesity effects of tofogliflozin in people with type 2 diabetes: Post‐hoc analyses. Endocrinology, Diabetes & Metabolism. 2024. doi:10.1002/edm2.461
BibTeX
@article{Takamura2024,
author = {Takamura, Toshinari and Kaku, Kohei and Yoshida, Akihiro and Kusakabe, Hiromi and Nakamura, Hiroyuki and Suganami, Hideki},
title = {Reductions in liver enzymes are associated with anti‐hyperglycaemic and anti‐obesity effects of tofogliflozin in people with type 2 diabetes: Post‐hoc analyses},
journal = {Endocrinology, Diabetes & Metabolism},
year = {2024},
doi = {10.1002/edm2.461}
}
EUVIMED